Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimus
Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimus
复制标题
DOI：
10.1093/ndt/gfh884
复制
发表时间：
2005-08-01
影响因子：
6.1
通讯作者：
Jothy, S
中科院分区：
文献类型：
--
作者：
Zaltzman, JS;Prasad, R;Jothy, S
淋巴样肿瘤仍然是实体器官移植后的严重并发症。最近的数据表明，在10年期间，患淋巴瘤的风险是普通人群的11.8倍[1]。虽然在移植后的第一年内风险最大，但在整个移植后期间，发病率仍然很高。危险因素包括Epstein-Barr病毒(EBV)的无节制增殖和总体免疫抑制负担[2，3]。移植后淋巴组织增生性疾病(PTLD)也可能发生在同种异体移植物内，并可能被误认为急性排斥反应。MTOR抑制剂西罗莫司目前正在作为一种抗肿瘤药物进行研究，在实体器官移植中使用它作为免疫抑制剂与较低的移植后恶性肿瘤风险有关，包括PTLD[4，5]。
Lymphoid neoplasia has remained a serious complication following solid organ transplantation. Recent data suggest an 11.8-fold higher risk of lymphoma compared with the general population over a 10 year period [1]. Although the risk is greatest within the first year posttransplant, the incidence remains high throughout the entire post-transplant period. Risk factors include unrestrained proliferation of Epstein–Barr virus (EBV) and the overall immunosuppression burden [2, 3]. Post-transplant lymphoproliferative disorder (PTLD) may also occur within the allograft and may be mistaken for acute rejection. The mTOR inhibitor sirolimus is currently under investigation as an antitumour agent, and its use as an immunosuppressive agent in solid organ transplants has been associated with a lower risk of post-transplant malignancies, including PTLD [4, 5].